Steroid drugs need stronger warnings, health group says
July 26--STEROID DRUGS SUCH AS PREDNISONE -- taken by 25.5 million Americans for arthritis, cancer, transplants and other conditions -- need stronger consumer warnings about a rare, but possibly irreversible vision impairment, a University of Michigan eye doctor and the consumer Public Citizen organization said today in a federal petition for stronger warning labels on the drugs. The problem, chorioretinopathy, which causes distortion in vision, is not well known to doctors, UM's Jonathan Trobe said. Given the number of people who take the drugs, "it's useful to know that a lot of visual complications are associated with steroids and if people develop a problem they should see an eye care specialist," said Trobe, professor of ophthalmology and neurology at U-M. Trobe joined the non-profit Washington D.C. organization calling for stronger and more consistent warnings about the drugs. Known generically as glucocorticosteriods, the medicines have been on the market for decades. Only two manufacturers of more than a dozen list the complication on drug labels as a potential side effect, said Dr. Michael Carome, deputy director of Public Citizen's Health Research Group, a Washington D.C. non-profit organization. The problem may go away on its own but can come back and lead to permanent visual loss, particularly in the center of the eye, Carome said. There are no large studies of the problem, only case reports describing occasional patient stories, he said. The federal Food and Drug Administration lists petitions on its Web site, www.regulations.gov, typically within a few weeks after a petition is filed, and invites the public to comment on the proposal. The Public Citizen Web site, www.citizen.org, has copies of the petition. Trobe said patients who took the drugs but did not develop eye problems are unlikely to be at risk of developing them now. A spokesman for the Generic Pharmaceutical Association, a Washington, D.C. trade organization representing generic manufacturers, said the group was "we still reviewing it and don't have a comment" on the petition. Contact Patricia Anstett: 313-222-5021 or [email protected] To see more of the Detroit Free Press, or to subscribe to the newspaper, go to http://www.freep.com Distributed by McClatchy-Tribune Information Services. For more information about the content services offered by McClatchy-Tribune Information Services (MCT), visit www.mctinfoservices.com. *These statements have not been evaluated by the Food and Drug Administration. These products are not intended to
diagnose, treat, cure or prevent any disease.
The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician. All Contents Copyright 1995-2011 Life Extension Foundation All rights reserved.

Source: http://lghttp.5872.nexcesscdn.net/804B77/magento/media/docs/disease2.pdf


REKLISTAN 2010 75 rEKommENdErAd FySISK AKtIvItEt vId ArtroS, LåNGvArIG SmÄrtA uNS och FIbromyALGI ArtroS Träningen bör inledningsvis ske som anpassad träning under ledning av sjukgymnast. Styrketräning kompletterad med rörlighet, balans och koordinationsfrämjande träning bör vara individuellt avpassad och ske 3 gånger/v. Konditionsfrämjande träning av mått-lig intensi


Lupin LUPN.NS LPC IN EQUITY: HEALTH CARE & PHARMACEUTICALS Good approvals- Monodox and Cipro OS Global Markets Research 6 March 2014 Quick Note Target price Lupin gains FDA approval for generic Monodox and Cipro OS Closing price Limited competition and supply constraints make Monodox an interesting opportunity for Lupin Research analysts Monodox appr

Copyright © 2009-2018 Drugs Today